Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin crossover study in non-diabetic proteinuric chronic kidney disease
NL-OMON47662Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in 24-hour proteinuria. Started Nov 2017; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON47662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47662.